Marzeptacog alfa

Drug Profile

Marzeptacog alfa

Alternative Names: CB 813; CB 813d; Marzeptacog alpha; PF-05280602; PF-5280602; Recombinant Factor VIIa variant (813d) - Pfizer

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catalyst Biosciences
  • Class Blood coagulation factors; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haemophilia; Surgical blood loss

Most Recent Events

  • 26 Jun 2017 Pharmacokinetics results from a preclinical trial in Haemophilia B released by Catalyst
  • 30 Mar 2017 Catalyst Biosciences plans a phase II/III trial for Haemophilia (SC), in the fourth quarter of 2017
  • 01 Feb 2017 Pharmacodynamics and pharmacokinetics data from a preclinical in Haemophilia A and B released by Catalyst Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top